pharmaphorum2d
After disappointing trial, Editas puts lead CRISPR drug on hold
The BRILLIANCE study of EDIT-101 in Leber congenital amaurosis type 10 (LCA10) – an inherited form of blindness – was reported to be the first 'in vivo' CRISPR/Cas9 medicine to be administered ...
PFG Investments LLC Grows Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)
PFG Investments LLC lifted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 9.9% in the 4th quarter, ...
Exchange Traded Concepts LLC Decreases Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)
Exchange Traded Concepts LLC trimmed its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 16.0% during the fourth quarter, according to the company in its most recent Form ...
The Scientist6mon
A CRISPR Tool for Tinkering with the Human Transcriptome
CRISPR-guided endonucleases were an obvious route, but for RNA, the options were few and imperfect. Cas13 proved useful for RNA knockdown, but it caused collateral damage to non-target RNA. Although ...
Morgan Stanley Sticks to Their Buy Rating for Crispr Therapeutics AG (CRSP)
In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), ...